New Pulmonary Hypertension Study Findings Have Been Reported from Houston Methodist Hospital (Management of Pulmonary Hypertension Associated With Valvular Heart Disease With Angiotensin-receptor Neprilysin Inhibitor).

A new report from Houston Methodist Hospital discusses the management of pulmonary hypertension associated with valvular heart disease using an angiotensin-receptor neprilysin inhibitor (ARNI). The research highlights the potential role of ARNI in treating combined pre- and postcapillary pulmonary hypertension, independent of its effect on pulmonary capillary wedge pressure and cardiac output. The study concludes that future prospective trials are needed to further evaluate the use of ARNIs in the treatment of valvular heart disease-associated pulmonary hypertension. [Extracted from the article]